A_randomized_trial_evaluating_leuprolide_acetate_before_hysterectomy_as_treatment_for_leiomyomas._Fifty_premenopausal_patients_requiring_hysterectomy_as_treatment_for_symptomatic_uterine_leiomyomas,_which_were_the_size_of_14_to_18_weeks'_gestation,_were_randomized_into_two_groups_to_determine_whether_preoperative_gonadotropin-releasing_hormone_agonist_would_increase_the_feasibility_of_vaginal_rather_than_abdominal_hysterectomy._The_control_group_(group_A;_n_=_25)_did_not_receive_preoperative_gonadotropin-releasing_hormone_agonist,_but_patients_in_Group_B_(n_=_25)_received_2_months_of_gonadotropin-releasing_hormone_agonist_before_undergoing_hysterectomy._Patients_in_the_two_groups_were_similar_with_respect_to_age,_gravidity,_parity,_pretreatment_uterine_size,_and_hemoglobin_and_hematocrit_levels._Patients_in_group_B_had_an_increase_in_hemoglobin_levels_(10.75_to_12.12_gm/dl,_p_less_than_0.05)_and_a_decrease_in_uterine_volume_(1086.7_to_723.4_ml,_p_less_than_0.05)_after_8_weeks_of_agonist_therapy_and_were_more_likely_to_undergo_vaginal_hysterectomy_(76.0%_vs_16%)._Patients_in_group_B_also_had_shorter_hospitalizations_(5.2_vs_3.8_days,_p_less_than_0.05)._We_conclude_that_the_administration_of_gonadotropin-releasing_hormone_agonist_for_2_months_followed_by_vaginal_hysterectomy_is_preferable_to_abdominal_hysterectomy_in_selected_patients_with_uterine_leiomyomas.